Telomerase activity in patients with transitional cell carcinoma: a preliminary study.
BACKGROUND
Telomerase activity is not detectable in normal cells, and their telomers shorten until the chromosome is unable to replicate. Immortal cells have short but stable chromosomes and increased telomerase activity. Transitional cell carcinoma (TCC) has only a few useful markers of diagnostic or prognostic importance. The objective of this study was to determine whether there was a correlation between telomerase activity and the grade or stage of TCC, and whether the enzyme's activity could serve as a biochemical marker of this tumor.


METHODS
The study included 29 patients with TCC. From each patient, samples of urine cells were obtained, and a cup biopsy was taken from an apparently normal area as well as from a part of the bladder tumor resected transurethrally. Control uroepithelial biopsies were taken from normal transitional cell sites from non-TCC patients. Biopsies or cells were subjected to either histologic examination or telomerase activity determination.


RESULTS
Twenty-six of 29 (90%) of the tumor biopsies exhibited telomerase activity. Most of the cup biopsies were categorized as metaplastic or dysplastic, and 20 of 29 (69%) of these exhibited telomerase activity. Telomerase activity was found in 17 of 21 (81%) of the urine cells but in only 3 of 14 (21%) of control urine cells. All (10 of 10) of the uroepithelial biopsies taken from non-TCC patients did not show any telomerase activity.


CONCLUSIONS
In this study, almost all tumor biopsies exhibited telomerase activity. The high incidence of telomerase activity found in cup biopsies of the malignant field uroepithelial cells from cup biopsies of TCC patients may suggest that telomerase could be activated early in carcinogenesis. A high incidence of telomerase activity was found in voided uroepithelial cells of TCC patients; however, no correlation between this activity and the histologic determination of grading and staging of the tumor was found.
Rahat
M A
MA
Immunology Research Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
Lahat
N
N
Gazawi
H
H
Resnick
M B
MB
Sova
Y
Y
Ben-Ari
G
G
Cohen
M
M
Stein
A
A
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000652:urine; D001706:Biopsy / Q000379:methods; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000473:pathology / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D019098:Telomerase / Q000032:analysis* / Q000652:urine; D014407:Tumor Cells, Cultured / Q000737:chemistry; D001743:Urinary Bladder / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000652:urine
D014408:Biomarkers, Tumor; D019098:Telomerase